Patient Preferences for Treatment Characteristics of Janus Kinase Inhibitors for Alopecia Areata: A Discrete Choice Experiment

    May 2026 in “ Journal of Dermatological Treatment ”
    Natasha Mesinkovska, Arash Mostaghimi, Kathleen L. Deering … Thomas J. Ferro
    Studysummary In this study, adults with significant alopecia areata were surveyed on their preferences for JAK inhibitor treatments, revealing a strong priority for scalp hair regrowth effectiveness and quicker initial regrowth over dosing convenience.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →

    Research cited in this study 14

    1. The Beard Score: A Practical Tool to Assess Beard Involvement in Alopecia Areata International Journal of Dermatology · 2026
    2. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase 1/2 Inhibitor, in Adults with Alopecia Areata: Results from the THRIVE-AA2 Phase 3, Randomized, Double-Blind, Controlled Trial Journal of the American Academy of Dermatology · 2025
    3. Patient Preferences in the Treatment of Alopecia Areata: A Review of the Literature JAAD reviews. · 2024
    4. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    5. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    6. Treatment Preferences of Adults and Adolescents with Alopecia Areata: A Discrete Choice Experiment Journal of dermatology · 2023
    7. Treatments for Alopecia Areata: A Network Meta-Analysis The Cochrane library · 2023
    8. The Invisible Impact Of A Visible Disease: Psychosocial Impact Of Alopecia Areata Dermatology and Therapy · 2023
    9. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    10. Factors Influencing Alopecia Areata Treatment Decisions: A Qualitative Assessment JAAD International · 2022
    11. Immunology of Alopecia Areata Central-European Journal of Immunology/Central European Journal of Immunology · 2020
    12. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    13. Alopecia Areata: A Comprehensive Review of Pathogenesis and Management Clinical Reviews in Allergy & Immunology · 2017
    14. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014